OverviewSuggest Edit

Kuros Biosciences engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The Сompany's synthetic orthobiologics pipeline products comprise MagnetOs Granules EU and MagnetOs Putty EU for the treatment of orthopedics, spinal, and dental problems; and MagnetOs Granules US and MagnetOs Putty US for the treatment of spinal fusion.
TypePublic
Founded2000
HQSchlieren, CH
Websitekurosbio.com

Latest Updates

Employees (est.) (Jul 2021)46
Share Price (Nov 2021)CHF2.2
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Kuros Biosciences

Michael Grau

Michael Grau

Chief Financial Officer
Joost de Bruijn

Joost de Bruijn

Chief Executive Officer, Director
Alistair Irvine

Alistair Irvine

Chief Business Officer
Phillippe Saudan

Phillippe Saudan

Chief Development Officer
Pascal Longlade

Pascal Longlade

Chief Medical Officer
Scott Bruder

Scott Bruder

Non-Executive Director
Show more

Kuros Biosciences Office Locations

Kuros Biosciences has offices in Schlieren, Burlington and Bilthoven
Schlieren, CH (HQ)
25 Wagistrasse
Bilthoven, NL
Professor Bronkhorstlaan 10, G 48
Burlington, MA, US
111 S Bedford St #108
Show all (3)

Kuros Biosciences Financials and Metrics

Kuros Biosciences Revenue

Market capitalization (10-Nov-2021)

70.5m

Closing stock price (10-Nov-2021)

2.2
Kuros Biosciences's current market capitalization is CHF70.5 m.
Show all financial metrics

Kuros Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Kuros Biosciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Kuros Biosciences Online and Social Media Presence

Embed Graph

Kuros Biosciences News and Updates

Kuros Biosciences Reports Continued Increase in MagnetOs U.S. Sales

Ad hoc announcement pursuant to Article 53 of the SIX listing rules Ad hoc announcement pursuant to Article 53 of the SIX listing rules

Kuros Biosciences to Showcase New MagnetOs Products at NASS 2021 Annual Meeting

SCHLIEREN (ZURICH), Switzerland, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it will showcase new products in the MagnetOs range at the 36th Annual Meeting of the North American Spine Soc…

Kuros Biosciences to Present at Upcoming Clinical and Investor Conferences

SCHLIEREN (ZURICH), Switzerland, March 10, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that the company will present at two major European conferences in March, b…

Kuros Biosciences Announces MagnetOs Sales and Distribution Agreements Across Northern Europe

SCHLIEREN (ZURICH), Switzerland, March 02, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN) today announced that it has signed sales and distribution agreements for MagnetOs bone graft, covering the Netherlands, Switzerland, Austria, and Finland. These add to an existing agreement in the Un…

Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PTH

SCHLIEREN (ZURICH), Switzerland, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Kuros Biosciences, a leader in next generation bone graft technologies, today announced that the first patient has been treated in the STRUCTURE trial, investigating Fibrin-PTH (KUR-113) for transforaminal lumbar interbody fusion …
Show more

Kuros Biosciences Frequently Asked Questions

  • When was Kuros Biosciences founded?

    Kuros Biosciences was founded in 2000.

  • Who are Kuros Biosciences key executives?

    Kuros Biosciences's key executives are Michael Grau, Joost de Bruijn and Alistair Irvine.

  • How many employees does Kuros Biosciences have?

    Kuros Biosciences has 46 employees.

  • Who are Kuros Biosciences competitors?

    Competitors of Kuros Biosciences include Dermavant Sciences, Biosearch Life and Alnylam Pharmaceuticals.

  • Where is Kuros Biosciences headquarters?

    Kuros Biosciences headquarters is located at 25 Wagistrasse, Schlieren.

  • Where are Kuros Biosciences offices?

    Kuros Biosciences has offices in Schlieren, Burlington and Bilthoven.

  • How many offices does Kuros Biosciences have?

    Kuros Biosciences has 3 offices.